IMMUNEONCO-B (01541): Drug Evaluation Center Approves Phase III Clinical Study Protocol for IMM0306 in Treating Relapsed/Refractory Follicular Lymphoma

Stock News11-27

IMMUNEONCO-B (01541) announced that the company has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the Phase III clinical study protocol of IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma. This marks an acceleration in the development of innovative therapies for this condition.

IMM0306, independently developed by the group, is a bispecific molecule targeting both CD47 and CD20, making it the first globally to enter clinical-stage development as a dual-targeting bispecific molecule for these markers. IMM0306 works by inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, while enhancing Fc-FcγRIIa and Fc-FcγRIIIa interactions to activate macrophages and NK cells. It preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving therapeutic outcomes.

As of the announcement date, the group holds global intellectual property and commercialization rights for IMM0306.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176417596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 12:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176417596","market":"fut","top_or_hot":-1,"title":"IMMUNEONCO-B (01541): Drug Evaluation Center Approves Phase III Clinical Study Protocol for IMM0306 in Treating Relapsed/Refractory Follicular Lymphoma","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) announced that the company has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the Phase III clinical study protocol of IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma. This marks an acceleration in the development of innovative therapies for this condition.</p>\n<p>IMM0306, independently developed by the group, is a bispecific molecule targeting both CD47 and CD20, making it the first globally to enter clinical-stage development as a dual-targeting bispecific molecule for these markers. IMM0306 works by inhibiting the CD47-SIRPα interaction to block the \"don't eat me\" signal, while enhancing Fc-FcγRIIa and Fc-FcγRIIIa interactions to activate macrophages and NK cells. It preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving therapeutic outcomes.</p>\n<p>As of the announcement date, the group holds global intellectual property and commercialization rights for IMM0306.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541): Drug Evaluation Center Approves Phase III Clinical Study Protocol for IMM0306 in Treating Relapsed/Refractory Follicular Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541): Drug Evaluation Center Approves Phase III Clinical Study Protocol for IMM0306 in Treating Relapsed/Refractory Follicular Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 12:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) announced that the company has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the Phase III clinical study protocol of IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma. This marks an acceleration in the development of innovative therapies for this condition.</p>\n<p>IMM0306, independently developed by the group, is a bispecific molecule targeting both CD47 and CD20, making it the first globally to enter clinical-stage development as a dual-targeting bispecific molecule for these markers. IMM0306 works by inhibiting the CD47-SIRPα interaction to block the \"don't eat me\" signal, while enhancing Fc-FcγRIIa and Fc-FcγRIIIa interactions to activate macrophages and NK cells. It preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving therapeutic outcomes.</p>\n<p>As of the announcement date, the group holds global intellectual property and commercialization rights for IMM0306.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1176417596","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176417596","pubTimestamp":1764218293,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) announced that the company has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the Phase III clinical study...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","BK1161":"生物科技","BK4134":"信息科技咨询与其它服务","III":"信息服务"},"translate_title":"IMMUNEONCO-B(01541)：药审中心批准IMM0306治疗复发/难治性滤泡性淋巴瘤的III期临床研究方案","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1,"III":1},"content_text":"IMMUNEONCO-B (01541) announced that the company has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the Phase III clinical study protocol of IMM0306 combined with lenalidomide in treating relapsed/refractory follicular lymphoma. This marks an acceleration in the development of innovative therapies for this condition.\nIMM0306, independently developed by the group, is a bispecific molecule targeting both CD47 and CD20, making it the first globally to enter clinical-stage development as a dual-targeting bispecific molecule for these markers. IMM0306 works by inhibiting the CD47-SIRPα interaction to block the \"don't eat me\" signal, while enhancing Fc-FcγRIIa and Fc-FcγRIIIa interactions to activate macrophages and NK cells. It preferentially binds to CD20 over CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving therapeutic outcomes.\nAs of the announcement date, the group holds global intellectual property and commercialization rights for IMM0306.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176417596","isCrawlerRequest":true}